• Prima Biomed Ltd., of Sydney, Australia, said the Korean Ministry of Food and Drug Safety granted approval to begin the Phase II/III CANcer VAccine Study (CANVAS) of CVac at several sites. The company expects the sites in Korea – the first in Asia – to begin recruiting in several weeks.